Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant
Emerging SARS-CoV-2 variants of concern (VOCs) raises concerns regarding vaccine efficacy. Here, the authors evaluate the neutralizing antibody, and cellular response elicited following inactivated vaccine immunization, and mRNA booster, against the Omicron variant.
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-05-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-022-30340-5 |
| _version_ | 1811235434623139840 |
|---|---|
| author | Fanglei Zuo Hassan Abolhassani Likun Du Antonio Piralla Federico Bertoglio Leire de Campos-Mata Hui Wan Maren Schubert Irene Cassaniti Yating Wang Josè Camilla Sammartino Rui Sun Stelios Vlachiotis Federica Bergami Makiko Kumagai-Braesch Juni Andréll Zhaoxia Zhang Yintong Xue Esther Veronika Wenzel Luigi Calzolai Luca Varani Nima Rezaei Zahra Chavoshzadeh Fausto Baldanti Michael Hust Lennart Hammarström Harold Marcotte Qiang Pan-Hammarström |
| author_facet | Fanglei Zuo Hassan Abolhassani Likun Du Antonio Piralla Federico Bertoglio Leire de Campos-Mata Hui Wan Maren Schubert Irene Cassaniti Yating Wang Josè Camilla Sammartino Rui Sun Stelios Vlachiotis Federica Bergami Makiko Kumagai-Braesch Juni Andréll Zhaoxia Zhang Yintong Xue Esther Veronika Wenzel Luigi Calzolai Luca Varani Nima Rezaei Zahra Chavoshzadeh Fausto Baldanti Michael Hust Lennart Hammarström Harold Marcotte Qiang Pan-Hammarström |
| author_sort | Fanglei Zuo |
| collection | DOAJ |
| description | Emerging SARS-CoV-2 variants of concern (VOCs) raises concerns regarding vaccine efficacy. Here, the authors evaluate the neutralizing antibody, and cellular response elicited following inactivated vaccine immunization, and mRNA booster, against the Omicron variant. |
| first_indexed | 2024-04-12T11:50:51Z |
| format | Article |
| id | doaj.art-cca0ad8fbc5c424fad461b3100fc19cf |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-04-12T11:50:51Z |
| publishDate | 2022-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-cca0ad8fbc5c424fad461b3100fc19cf2022-12-22T03:34:10ZengNature PortfolioNature Communications2041-17232022-05-011311810.1038/s41467-022-30340-5Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variantFanglei Zuo0Hassan Abolhassani1Likun Du2Antonio Piralla3Federico Bertoglio4Leire de Campos-Mata5Hui Wan6Maren Schubert7Irene Cassaniti8Yating Wang9Josè Camilla Sammartino10Rui Sun11Stelios Vlachiotis12Federica Bergami13Makiko Kumagai-Braesch14Juni Andréll15Zhaoxia Zhang16Yintong Xue17Esther Veronika Wenzel18Luigi Calzolai19Luca Varani20Nima Rezaei21Zahra Chavoshzadeh22Fausto Baldanti23Michael Hust24Lennart Hammarström25Harold Marcotte26Qiang Pan-Hammarström27Department of Biosciences and Nutrition, Karolinska InstitutetDepartment of Biosciences and Nutrition, Karolinska InstitutetDepartment of Biosciences and Nutrition, Karolinska InstitutetMolecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San MatteoDepartment of Biotechnology, Institute of Biochemistry, Biotechnology and Bioinformatics, Technische Universität BraunschweigDepartment of Biosciences and Nutrition, Karolinska InstitutetDepartment of Biosciences and Nutrition, Karolinska InstitutetDepartment of Biotechnology, Institute of Biochemistry, Biotechnology and Bioinformatics, Technische Universität BraunschweigMolecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San MatteoDepartment of Biosciences and Nutrition, Karolinska InstitutetMolecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San MatteoDepartment of Biosciences and Nutrition, Karolinska InstitutetDepartment of Biosciences and Nutrition, Karolinska InstitutetMolecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San MatteoDivision of Transplantation Surgery, CLINTEC, Karolinska Institutet at Karolinska University HospitalScience for Life Laboratory, Department of Biochemistry and Biophysics, Stockholm UniversityDepartment of Aging Neurology orthopedics, Karolinska University Hospital HuddingeDepartment of Immunology, Peking University Health Science CenterDepartment of Biotechnology, Institute of Biochemistry, Biotechnology and Bioinformatics, Technische Universität BraunschweigEuropean Commission, Joint Research CentreInstitute for Research in Biomedicine, Università della Svizzera italiana (USI)Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical SciencesPediatric Infections Research Center, Mofid Children’s Hospital, Shahid Beheshti University of Medical SciencesMolecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San MatteoDepartment of Biotechnology, Institute of Biochemistry, Biotechnology and Bioinformatics, Technische Universität BraunschweigDepartment of Biosciences and Nutrition, Karolinska InstitutetDepartment of Biosciences and Nutrition, Karolinska InstitutetDepartment of Biosciences and Nutrition, Karolinska InstitutetEmerging SARS-CoV-2 variants of concern (VOCs) raises concerns regarding vaccine efficacy. Here, the authors evaluate the neutralizing antibody, and cellular response elicited following inactivated vaccine immunization, and mRNA booster, against the Omicron variant.https://doi.org/10.1038/s41467-022-30340-5 |
| spellingShingle | Fanglei Zuo Hassan Abolhassani Likun Du Antonio Piralla Federico Bertoglio Leire de Campos-Mata Hui Wan Maren Schubert Irene Cassaniti Yating Wang Josè Camilla Sammartino Rui Sun Stelios Vlachiotis Federica Bergami Makiko Kumagai-Braesch Juni Andréll Zhaoxia Zhang Yintong Xue Esther Veronika Wenzel Luigi Calzolai Luca Varani Nima Rezaei Zahra Chavoshzadeh Fausto Baldanti Michael Hust Lennart Hammarström Harold Marcotte Qiang Pan-Hammarström Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant Nature Communications |
| title | Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant |
| title_full | Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant |
| title_fullStr | Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant |
| title_full_unstemmed | Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant |
| title_short | Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant |
| title_sort | heterologous immunization with inactivated vaccine followed by mrna booster elicits strong immunity against sars cov 2 omicron variant |
| url | https://doi.org/10.1038/s41467-022-30340-5 |
| work_keys_str_mv | AT fangleizuo heterologousimmunizationwithinactivatedvaccinefollowedbymrnaboosterelicitsstrongimmunityagainstsarscov2omicronvariant AT hassanabolhassani heterologousimmunizationwithinactivatedvaccinefollowedbymrnaboosterelicitsstrongimmunityagainstsarscov2omicronvariant AT likundu heterologousimmunizationwithinactivatedvaccinefollowedbymrnaboosterelicitsstrongimmunityagainstsarscov2omicronvariant AT antoniopiralla heterologousimmunizationwithinactivatedvaccinefollowedbymrnaboosterelicitsstrongimmunityagainstsarscov2omicronvariant AT federicobertoglio heterologousimmunizationwithinactivatedvaccinefollowedbymrnaboosterelicitsstrongimmunityagainstsarscov2omicronvariant AT leiredecamposmata heterologousimmunizationwithinactivatedvaccinefollowedbymrnaboosterelicitsstrongimmunityagainstsarscov2omicronvariant AT huiwan heterologousimmunizationwithinactivatedvaccinefollowedbymrnaboosterelicitsstrongimmunityagainstsarscov2omicronvariant AT marenschubert heterologousimmunizationwithinactivatedvaccinefollowedbymrnaboosterelicitsstrongimmunityagainstsarscov2omicronvariant AT irenecassaniti heterologousimmunizationwithinactivatedvaccinefollowedbymrnaboosterelicitsstrongimmunityagainstsarscov2omicronvariant AT yatingwang heterologousimmunizationwithinactivatedvaccinefollowedbymrnaboosterelicitsstrongimmunityagainstsarscov2omicronvariant AT josecamillasammartino heterologousimmunizationwithinactivatedvaccinefollowedbymrnaboosterelicitsstrongimmunityagainstsarscov2omicronvariant AT ruisun heterologousimmunizationwithinactivatedvaccinefollowedbymrnaboosterelicitsstrongimmunityagainstsarscov2omicronvariant AT steliosvlachiotis heterologousimmunizationwithinactivatedvaccinefollowedbymrnaboosterelicitsstrongimmunityagainstsarscov2omicronvariant AT federicabergami heterologousimmunizationwithinactivatedvaccinefollowedbymrnaboosterelicitsstrongimmunityagainstsarscov2omicronvariant AT makikokumagaibraesch heterologousimmunizationwithinactivatedvaccinefollowedbymrnaboosterelicitsstrongimmunityagainstsarscov2omicronvariant AT juniandrell heterologousimmunizationwithinactivatedvaccinefollowedbymrnaboosterelicitsstrongimmunityagainstsarscov2omicronvariant AT zhaoxiazhang heterologousimmunizationwithinactivatedvaccinefollowedbymrnaboosterelicitsstrongimmunityagainstsarscov2omicronvariant AT yintongxue heterologousimmunizationwithinactivatedvaccinefollowedbymrnaboosterelicitsstrongimmunityagainstsarscov2omicronvariant AT estherveronikawenzel heterologousimmunizationwithinactivatedvaccinefollowedbymrnaboosterelicitsstrongimmunityagainstsarscov2omicronvariant AT luigicalzolai heterologousimmunizationwithinactivatedvaccinefollowedbymrnaboosterelicitsstrongimmunityagainstsarscov2omicronvariant AT lucavarani heterologousimmunizationwithinactivatedvaccinefollowedbymrnaboosterelicitsstrongimmunityagainstsarscov2omicronvariant AT nimarezaei heterologousimmunizationwithinactivatedvaccinefollowedbymrnaboosterelicitsstrongimmunityagainstsarscov2omicronvariant AT zahrachavoshzadeh heterologousimmunizationwithinactivatedvaccinefollowedbymrnaboosterelicitsstrongimmunityagainstsarscov2omicronvariant AT faustobaldanti heterologousimmunizationwithinactivatedvaccinefollowedbymrnaboosterelicitsstrongimmunityagainstsarscov2omicronvariant AT michaelhust heterologousimmunizationwithinactivatedvaccinefollowedbymrnaboosterelicitsstrongimmunityagainstsarscov2omicronvariant AT lennarthammarstrom heterologousimmunizationwithinactivatedvaccinefollowedbymrnaboosterelicitsstrongimmunityagainstsarscov2omicronvariant AT haroldmarcotte heterologousimmunizationwithinactivatedvaccinefollowedbymrnaboosterelicitsstrongimmunityagainstsarscov2omicronvariant AT qiangpanhammarstrom heterologousimmunizationwithinactivatedvaccinefollowedbymrnaboosterelicitsstrongimmunityagainstsarscov2omicronvariant |